

Amendments to the Claims

1.-36. (canceled)

37. (currently amended) An immunogenic composition comprising:

(a) a peptide consisting essentially of a tau amino acid sequence ~~selected from the group consisting of~~

- ~~(i) — Lys-Glu-Ser-Pro-Leu-Gln (residues 44-49 in SEQ ID NO:1),~~
- ~~(ii) — Tyr-Ser-Ser-Pro-Gly-Ser-Pro (residues 197-203 in SEQ ID NO:1),~~
- ~~(iii) — Pro-Gly-Ser-Pro-Gly-Thr (residues 200-205 in SEQ ID NO:1),~~
- ~~(iv) — Tyr-Ser-Ser-Pro-Gly-Ser-Pro-Gly-Thr-Pro-Gly-Ser (residues 197-208 in SEQ ID NO:1),~~
- ~~(v) — Pro-Lys-Ser-Pro-Ser-Ser (residues 233-238 in SEQ ID NO:1),~~
- ~~(vi) — Gly-Asp-Thr-Ser-Pro-Arg-His (residues 401-407 in SEQ ID NO:1),~~
- ~~(vii) — Met-Val-Asp-Ser-Pro-Gln-Leu (residues 419-425 in SEQ ID NO:1),~~
- ~~(viii) — Pro-Leu-Gln-Thr-Pro-Thr-Glu (residues 47-53 in SEQ ID NO:1),~~
- ~~(ix) — Leu-Lys-Glu-Ser-Pro-Leu-Gln-Thr-Pro-Thr-Glu-Asp (residues 43-54 in SEQ ID NO:1),~~
- ~~(x) — Ala-Lys-Ser-Thr-Pro-Thr-Ala (residues 66-72 in SEQ ID NO:1),~~
- ~~(xi) — Ile-Gly-Asp-Thr-Pro-Ser-Leu (residues 108-114 in SEQ ID NO:1),~~
- ~~(xii) — Lys-Ile-Ala-Thr-Pro-Arg-Gly-Ala (residues 150-157 in SEQ ID NO:1),~~
- ~~(xiii) — Pro-Ala-Lys-Thr-Pro-Pro-Ala (residues 172-178 in SEQ ID NO:1),~~
- ~~(xiv) — Ala-Pro-Lys-Thr-Pro-Pro-Ser (residues 178-184 in SEQ ID NO:1),~~
- ~~(xv) — Pro-Ala-Lys-Thr-Pro-Pro-Ala-Pro-Lys-Thr-Pro-Pro-Ser (residues 172-184 in SEQ ID NO:1),~~
- ~~(xvi) — Ser-Pro-Gly-Thr-Pro-Gly-Ser (residues 202-208 in SEQ ID NO:1),~~
- ~~(xvii) — Arg-Ser-Arg-Thr-Pro-Ser-Leu (residues 209-215 in SEQ ID NO:1),~~
- ~~(xviii) — Ser-Leu-Pro-Thr-Pro-Pro-Thr (residues 214-220 in SEQ ID NO:1),~~
- ~~(xix) — Arg-Ser-Arg-Thr-Pro-Ser-Leu-Pro-Pro-Thr-Pro-Pro-Thr (residues 209-220 in SEQ ID NO:1),~~
- ~~(xx) — Val-Val-Arg-Thr-Pro-Pro-Lys (residues 228-234 in SEQ ID NO:1),~~
- ~~(xxi) — Val-Val-Arg-Thr-Pro-Pro-Lys-Ser-Pro-Ser-Ser-Ala (residues 228-239 in SEQ ID NO:1),~~

~~(xxii) Lys-Ile-Gly-Ser-Thr-Glu-Asn-Leu-Lys (residues 259-267 in SEQ ID NO:1),~~

~~(xxiii) Lys-Cys-Gly-Ser-Lys-Asp-Asn-Ile-Lys (residues 290-298 in SEQ ID NO:1),~~

~~(xxiv) Lys-Cys-Gly-Ser-Leu-Gly-Asn-Ile-His (residues 321-329 in SEQ ID NO:1), and~~

~~(xxv) Lys-Ile-Gly-Ser-Leu-Asp-Asn-Ile-Thr-His. (residues 353-362 in SEQ ID NO:1);~~ conjugated to

- (b) a carrier molecule, wherein the carrier molecule induces or enhances an immune response to the peptide of (a).

38-41. (canceled)

42. (currently amended) The immunogenic composition of claim ~~39~~ 37, wherein the Ser (residue 262 of SEQ ID NO:1) is phosphorylated.

43. (canceled).

44. (currently amended) A method of producing an antibody to a tau peptide, the method comprising administering to an animal an antibody-producing amount of an immunogenic composition comprising:

- (a) a peptide consisting essentially of a tau amino acid sequence ~~selected from the group consisting of~~

~~(i) Lys-Glu-Ser-Pro-Leu-Gln (residues 44-49 in SEQ ID NO:1),~~

~~(ii) Tyr-Ser-Ser-Pro-Gly-Ser-Pro (residues 197-203 in SEQ ID NO:1),~~

~~(iii) Pro-Gly-Ser-Pro-Gly-Thr (residues 200-205 in SEQ ID NO:1),~~

~~(iv) Tyr-Ser-Ser-Pro-Gly-Ser-Pro-Gly-Thr-Pro-Gly-Ser (residues 197-208 in SEQ ID NO:1),~~

~~(v) Pro-Lys-Ser-Pro-Ser-Ser (residues 233-238 in SEQ ID NO:1),~~

~~(vi) Gly-Asp-Thr-Ser-Pro-Arg-His (residues 401-407 in SEQ ID NO:1),~~

~~(vii) Met-Val-Asp-Ser-Pro-Gln-Leu (residues 419-425 in SEQ ID NO:1),~~

~~(viii) Pro-Leu-Gln-Thr-Pro-Thr-Glu (residues 47-53 in SEQ ID NO:1),~~

~~(ix) Leu-Lys-Glu-Ser-Pro-Leu-Gln-Thr-Pro-Thr-Glu-Asp (residues 43-54 in SEQ ID NO:1),~~

~~(x) Ala-Lys-Ser-Thr-Pro-Thr-Ala (residues 66-72 in SEQ ID NO:1),~~

~~(xi) Ile-Gly-Asp-Thr-Pro-Ser-Leu (residues 108-114 in SEQ ID NO:1),~~

- ~~(xii) Lys Ile Ala Thr Pro Arg Gly Ala (residues 150-157 in SEQ ID NO:1),~~
- ~~(xiii) Pro Ala Lys Thr Pro Pro Ala (residues 172-178 in SEQ ID NO:1),~~
- ~~(xiv) Ala Pro Lys Thr Pro Pro Ser (residues 178-184 in SEQ ID NO:1),~~
- ~~(xv) Pro Ala Lys Thr Pro Pro Ala Pro Lys Thr Pro Pro Ser (residues 172-184 in SEQ ID NO:1),~~
- ~~(xvi) Ser Pro Gly Thr Pro Gly Ser (residues 202-208 in SEQ ID NO:1),~~
- ~~(xvii) Arg Ser Arg Thr Pro Ser Leu (residues 209-215 in SEQ ID NO:1),~~
- ~~(xviii) Ser Leu Pro Thr Pro Pro Thr (residues 214-220 in SEQ ID NO:1),~~
- ~~(xix) Arg Ser Arg Thr Pro Ser Leu Pro Pro Thr Pro Pro Thr (residues 209-220 in SEQ ID NO:1),~~
- ~~(xx) Val Val Arg Thr Pro Pro Lys (residues 228-234 in SEQ ID NO:1),~~
- ~~(xxi) Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala (residues 228-239 in SEQ ID NO:1),~~
- ~~(xxii) Lys-Ile-Gly-Ser-Thr-Glu-Asn-Leu-Lys (residues 259-267 in SEQ ID NO:1),~~
- ~~(xxiii) Lys-Cys-Gly-Ser-Lys-Asp-Asn-Ile-Lys (residues 290-298 in SEQ ID NO:1),~~
- ~~(xxiv) Lys-Cys-Gly-Ser-Leu-Gly-Asn-Ile-His (residues 321-329 in SEQ ID NO:1), and~~
- ~~(xxv) Lys-Ile-Gly-Ser-Leu-Asp-Asn-Ile-Thr-His. (residues 353-362 in SEQ ID NO:1); conjugated to~~

- (b) a carrier molecule, wherein the carrier molecule induces or enhances an immune response to the peptide of (a).

45-48. (canceled)

49. (currently amended) The method of claim 46 ~~44~~, wherein the Ser (residue 262 of SEQ ID NO:1) is phosphorylated.

50. (canceled)